Incretin Atlas › Trials › Phase 2b CTR20231695
Phase 2b CTR20231695
Bofanglutide (GZR18) · obesity
Design
- Molecule(s)
- Bofanglutide (GZR18)
- Population
- obesity
- Phase
- 2
- Participants
- 64
- Duration
- 30 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12 mg Q2W | obesity china | 30 | 52 | — | —−11.2 % vs −1.0 % estimand not specified | — | — | — | — | — | 0.0 | — | press release |
| 18 mg Q2W | obesity china | 30 | 53 | — | —−13.2 % vs −1.0 % estimand not specified | — | — | — | — | — | 0.0 | — | press release |
| 24 mg Q2W | obesity china | 30 | 52 | — | —−14.2 % vs −1.0 % estimand not specified | — | — | — | — | — | 0.0 | — | press release |
| 48 mg Q2W | obesity china | 30 | 64 | — | —−17.3 % vs −1.0 % estimand not specified | — | — | — | — | — | 0.0 | — | press release |
| 24 mg QW | obesity china | 30 | 53 | — | —−17.8 % vs −1.0 % estimand not specified | — | — | — | — | — | 0.0 | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (10)
- 12 mg Q2W · weight_unsp · press release
11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
- 12 mg Q2W · sae · press release, safety paragraph
No serious adverse events were reported in any treatment group.
- 18 mg Q2W · weight_unsp · press release
11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
- 18 mg Q2W · sae · press release, safety paragraph
No serious adverse events were reported in any treatment group.
- 24 mg Q2W · weight_unsp · press release
11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
- 24 mg Q2W · sae · press release, safety paragraph
No serious adverse events were reported in any treatment group.
- 48 mg Q2W · weight_unsp · press release
11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group
- 48 mg Q2W · sae · press release, safety paragraph
No serious adverse events were reported in any treatment group.
- 24 mg QW · weight_unsp · press release
In the QW 24 mg group, participants experienced a weight reduction of 17.78% (1.01)
- 24 mg QW · sae · press release, safety paragraph
No serious adverse events were reported in any treatment group.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Phase 2b CTR20231695. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b-ctr20231695/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.